← Eichor
Condition: Acute Lymphocytic Leukemia All Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Acute Lymphocytic Leukemia All

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of CTD402 in T-ALL/LBL Patients
Phase 1/Phase 2 · 8 location(s) · Imviva Bio · NCT07070219A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06387121Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros
NA · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT07313878Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/R
Phase 1/Phase 2 · 4 location(s) · Beijing GoBroad Hospital · NCT07070323Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Phase 1/Phase 2 · 2 location(s) · Chinese PLA General Hospital · NCT07008885Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Phase 1/Phase 2 · 7 location(s) · Leland Metheny · NCT03104491UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT05535855A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patie
Phase 2 · 13 location(s) · Center for International Blood and Marrow Transplant Researc · NCT06859424Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT01853631Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
Phase 1/Phase 2 · 11 location(s) · University Hospital Tuebingen · NCT05366218Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · John Lister · NCT05281809CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Phase 1/Phase 2 · 3 location(s) · Ottawa Hospital Research Institute · NCT03765177Pilot Imaging Study of Leukemia
Phase 1 · 3 location(s) · University of Oklahoma · NCT03633955Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantati
Phase 1 · 1 location(s) · Sawa Ito, MD · NCT07565220HPC Offered for PRESERVE Expansion
Phase N/A · 4 location(s) · Ossium Health, Inc. · NCT07145411Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding
NA · 1 location(s) · Donald Arnold · NCT06947044Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07053059Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Phase 2 · 1 location(s) · Case Comprehensive Cancer Center · NCT06904482Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02877303CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Unde
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT06059391Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r
Phase 1 · 23 location(s) · Imugene Limited · NCT03666000
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.